MoonLake Immunotherapeutics (MLTX)
52.02
+2.20
(+4.41%)
USD |
NASDAQ |
Nov 21, 16:00
52.02
0.00 (0.00%)
After-Hours: 19:48
MoonLake Immunotherapeutics Net Income (Quarterly): -35.39M for Sept. 30, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -35.39M |
| June 30, 2024 | -24.27M |
| March 31, 2024 | -13.67M |
| December 31, 2023 | -7.437M |
| September 30, 2023 | -9.426M |
| June 30, 2023 | -10.14M |
| March 31, 2023 | -9.005M |
| Date | Value |
|---|---|
| December 31, 2022 | -17.11M |
| September 30, 2022 | -10.11M |
| June 30, 2022 | -12.12M |
| March 31, 2022 | -15.88M |
| September 30, 2021 | -6.288M |
| June 30, 2021 | -32.69M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-35.39M
Minimum
Sep 2024
-6.288M
Maximum
Sep 2021
-15.66M
Average
-12.12M
Median
Jun 2022
Net Income (Quarterly) Benchmarks
| Novartis AG | 3.189B |
| AC Immune SA | 6.364M |
| CRISPR Therapeutics AG | -85.94M |
| Addex Therapeutics Ltd | 14.24M |
| NLS Pharmaceutics Ltd | -- |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 43.11M |
| EPS Diluted (Quarterly) | -0.56 |
| Enterprise Value | 2.655B |
| Earnings Yield | -2.44% |